Study: Pfizer-BioNTech vaccine effective against coronavirus variant detected in India


Two weeks after the second dose, the Pfizer-BioNTech COVID-19 vaccine was 88 percent effective against symptomatic disease from a coronavirus variant first identified in India that is spreading in the United Kingdom and could soon become the dominant strain there, a study by Public Health England found.
The results, released Saturday, are similar to the 93 percent effectiveness against another variant first identified in the U.K. last year, suggesting the vaccine still offers significant protection despite fears that the variant discovered in India, which is believed to be more contagious, would be resistant to vaccines. The research was conducted between April 5 and May 16.
The study also found that the vaccine developed by the University of Oxford and AstraZeneca, which has not been approved for emergency use by the Food and Drug Administration in the United States, was 60 percent effective against the variant first detected in India after two doses, similar to the 66 percent mark against the variant first detected in the U.K.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Although the study instills confidence in the vaccines, it also indicates that getting the full dosing regimen is crucial when it comes to maximizing protection against the virus. Both vaccines were 33 percent effective against symptomatic disease from the variant detected in India three weeks after the first dose, compared to 50 percent against the variant discovered in the U.K. Read more at Axios and The Guardian.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How to go on your own Race Across the World
The Week Recommends The BBC hit show is inspiring fans to choose low-budget adventures
-
The rebirth of Monaco
The Week Recommends The billionaires' playground is pulling out all the stops to entice Gen Z
-
Sudoku hard: June 3, 2025
The Week's daily hard sudoku puzzle
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows